Fort Washington Investment Advisors Inc. OH Has $47.40 Million Position in Haemonetics Corporation $HAE

Fort Washington Investment Advisors Inc. OH lifted its stake in Haemonetics Corporation (NYSE:HAE) by 17.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 841,017 shares of the medical instruments supplier’s stock after buying an additional 124,020 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Haemonetics were worth $47,400,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Kemnay Advisory Services Inc. bought a new position in Haemonetics during the fourth quarter valued at about $26,000. True Wealth Design LLC lifted its position in shares of Haemonetics by 6,700.0% in the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 335 shares during the period. Leonteq Securities AG acquired a new stake in shares of Haemonetics during the 4th quarter worth approximately $30,000. EverSource Wealth Advisors LLC grew its holdings in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares in the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in shares of Haemonetics in the fourth quarter valued at $34,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HAE has been the subject of several research reports. Citigroup raised their target price on Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, May 28th. BTIG Research restated a “buy” rating and issued a $84.00 price objective on shares of Haemonetics in a research note on Friday. JPMorgan Chase & Co. reduced their price objective on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Barrington Research decreased their target price on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. Finally, Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $78.33.

Haemonetics Price Performance

Shares of HAE stock opened at $77.34 on Friday. The stock’s fifty day simple moving average is $65.41 and its 200 day simple moving average is $66.87. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The firm has a market cap of $3.51 billion, a price-to-earnings ratio of 38.29, a P/E/G ratio of 1.56 and a beta of 0.56. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, analysts expect that Haemonetics Corporation will post 5.22 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.